SCHEMBL5205350

SCHEMBL5205350

Cc1ccc(NC(=O)c2cc(Cl)ccc2NC(=O)c2cnc(N3CCCN(C)CC3)cn2)nc1

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
F10 P00742 19/20 0.65
F2 P00734 1/20 0.49
KCNH2 Q12809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5204047 0.94 F10 (0.56) F10F2
SCHEMBL5205058 0.94 F10 (0.73) F10F2KCNH2
SCHEMBL5208105 0.93 F10 (0.65) F10F2
SCHEMBL5202028 0.89 F10 (0.72) F10
SCHEMBL5208024 0.89 F10 (0.64) F10F2KCNH2
SCHEMBL5205629 0.89 F10 (0.74) F10F2
SCHEMBL5207752 0.87 F10 (0.64) F10F2KCNH2
SCHEMBL5205288 0.87 F10 (0.58) F10KCNH2
SCHEMBL5208089 0.87 F10 (0.53) F10
SCHEMBL4850116 0.87 F10 (0.56) F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307444-B1 SUBSTITUTED HETEROCYCLIC AMIDES LILLY CO ELI (US) 2007-10-03 EP disclosed
US-7160878-B2 Substituted heterocyclic amides ELI LILLY AND COMPANY (US) 2007-01-09 US disclosed
US-7160878-B2 Substituted heterocyclic amides ELI LILLY AND COMPANY (US) 2007-01-09 US disclosed
US-7160878-B2 Substituted heterocyclic amides ELI LILLY AND COMPANY (US) 2007-01-09 US disclosed
US-20040097491-A1 Substituted heterocyclic amides HERRON DAVID KENT (US) 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097491-A1 Substituted heterocyclic amides F12, F11, F8 F10 11/4885F2 7/4885KCNH2 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.